Up to twice the risk of ALS, with no clear explanation for why: that is the gap the NFL’s $500,000 commitment to Champion Insights is designed to close. The funding backs a nationwide study enrolling up to 500 professional athletes, military veterans, and first responders, populations where ALS incidence runs well above the general public rate, to identify the genetic and biological factors driving that excess risk.
The study collects data remotely, using in-home blood draws and detailed surveys covering genetics, environmental exposures, and lifestyle. That design matters because it allows researchers to reach participants across the country without requiring them to travel to academic medical centers, which has historically constrained enrollment in ALS research. The research infrastructure builds on work already established through Answer ALS and ALS TDI’s ARC study, applying the same depth of biological and clinical data collection to a population with documented elevated risk. The scientific premise is that whatever biological mechanism makes high-performance individuals more susceptible to ALS probably also has relevance for the broader ALS population, making this a tractable shortcut into disease biology rather than a siloed occupational study.
The urgency of that question is sharpening in real time. A July 2026 study published in Neurology, led by Harvard T.H. Chan School of Public Health researchers, analyzed health records from nearly 9.2 million male veterans receiving VA care between 2000 and 2024 and found that 13,935 developed ALS, with rates varying by military branch in ways that point toward specific occupational or environmental exposures rather than service generally. Champion Insights is set up to probe exactly that kind of granularity, asking whether the shared biology of high-performers, traits that may confer competitive advantages, also loads the biological dice toward neurodegeneration.
The NFL’s commitment, announced October 5 on Good Morning America with Answer ALS founder Steve Gleason, who was diagnosed with ALS in 2011 and is the study’s first enrolled participant, adds financial weight to a question the research has circled for years without resolving. The number to watch now is how many of the 500 enrollment slots fill and whether the biological data they generate is rich enough to produce a testable mechanistic hypothesis, which is the step that turns a risk association into a drug target.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
